Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.133.94.82
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Autoimmune
Journal Scan

Adalimumab Shows No New Safety Concerns in Pediatric Patients With Autoimmune Disorders

Posted on

A meta-analysis of data from 7 global, randomized, open-label clinical trials and their open-label extensions showed a similar safety profile with adalimumab across autoimmune conditions assessed, including polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn’s disease. Currently, adalimumab has several indications in pediatric patients, including juvenile idiopathic arthritis and Crohn’s disease.

The analysis included 577 pediatric patients who received at least 1 dose of adalimumab, with a cumulative adalimumab exposure a 1440.7 patient-years. Across indications, the most commonly observed adverse effects (AE) included upper respiratory tract infections, nasopharyngitis, and headache. The most serious AE was infection, with 4.0 events per 100 patient-years reported. Pneumonia was the most common infection at 0.6 events per 100 patients-years. Patients with Crohn’s disease had the highest rate of serious infection at 6.6 events per 100 patient-years, followed by patients with juvenile idiopathic arthritis and psoriasis at 2.7 and 0.8 events per 100 patient-years, respectively. No malignancies were reported.

The study had several limitations, including a low number of patients in certain age groups (eg, <4 years) or with certain disease indications (eg, enthesitis-related arthritis). Read more here. Reference Horneff G, Seyger MMB, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn's disease. J Pediatr. 2018 Jul 25. pii: S0022-3476(18)30755-8. doi: 10.1016/j.jpeds.2018.05.042.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-